Stryker Corporation SYK
272.36
2.61
0.97%
as of 25 Sep
- Market cap
- $103.9B
- P/E
- 28.0×
Follow SYK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Stryker Corporation (SYK) EBITDA
Stryker Corporation's EBITDA for fiscal 2025 was $6.1B, up 28.3% from $4.7B in fiscal 2024. Over the twelve months to 30 June 2026 it was $6.8B. Over the past ten years it has ranged from $2.3B (fiscal 2015) to $6.1B (fiscal 2025) — the current reading is the highest in ten years. Stryker Corporation ranks 3rd of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $6.1B | 28.34% |
| FY2024 | $4.7B | (3.60%) |
| FY2023 | $4.9B | 28.05% |
| FY2022 | $3.8B | 7.41% |
| FY2021 | $3.6B | 17.76% |
| FY2020 | $3.0B | (13.06%) |
| FY2019 | $3.5B | 7.09% |
| FY2018 | $3.3B | 10.92% |
| FY2017 | $2.9B | 8.01% |
| FY2016 | $2.7B | 20.50% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $2.0B | 58.17% |
| Mar 2026 | $1.2B | (41.70%) |
| Dec 2025 | $2.1B | 46.81% |
| Sep 2025 | $1.4B | 2.48% |
| 42 more quarters | Free account |
Against its own ten years
Low $2.3B
High $6.1B
Ten-year median
$3.5B
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| ABT Abbott Laboratories compare | $10.8B |
| MDT Medtronic PLC compare | $9.7B |
| SYK Stryker Corporation | $6.8B |
| BSX Boston Scientific Corporation compare | $5.6B |
| PHG Koninklijke Philips N.V. compare | $3.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.3B |
| STE STERIS plc compare | $1.6B |
| EW Edwards Lifesciences Corporation compare | $1.6B |
| DXCM DexCom, Inc. compare | $1.4B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SYK
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement